Ke Chen, PhD

Ke Chen earned his PhD from Donghua University in 2018 with his research focusing on nucleic acid testing. After graduation, he joined Labcorp Central Laboratory Services as a genomics scientist.

In his current role, Ke is responsible for method validation and test assay troubleshooting. He has extensive knowledge in the field of molecular detection methods, especially in qPCR and next-generation sequencing.

Jane Craig, PhD

Dr. Jane Craig is a Scientist in Flow Cytometry Validation Services at Labcorp Central Labs. She works with biotech and pharmaceutical clients to build and validate custom flow cytometry panels to be used during clinical trials. Panels span a variety of topics and therapeutic areas, such as CART cell persistence, receptor occupancy, immune-phenotyping, and functional testing.

Jane has worked in flow cytometry for 7 years and has experience with the BD LSRFortessa, BD FACSCanto II, BD FACSLyric, and Bio-Rad ZE5 and has validated panels with up to 17 colors.

Nadia Ayala-Lopez, PhD, MLS (ASCP), DABCC, NRCC

Dr. Ayala-Lopez is director of clinical chemistry in medical affairs at Labcorp Drug Development where she provides medical, scientific, and regulatory support for the Central Laboratory Services in the areas of hematology, clinical chemistry, special chemistry, analytical chemistry, and toxicology. She also serves as the medical laboratory director for Labcorp Bioanalytical Services in Indianapolis, Indiana.

Labcorp awarded Forrester Research 2023 Customer Obsession Leadership Award

BURLINGTON, N.C. , June 14, 2023 /PRNewswire/ --  Labcorp  (NYSE: LH), a leading global life sciences company, is pleased to share that its executive vice president and chief marketing officer, Amy Summy , has been awarded the inaugural Forrester Customer Obsession Leadership Award, recognizing

Understanding the Bhas 42 cell transformation assay: A first step in detecting carcinogenesis

Responding to a need to provide testing solutions that may help reduce timelines, costs and complexities for our drug development partners, Labcorp is pleased to now offer the Bhas 42 cell transformation assay (CTA) in support of preclinical toxicology studies. 

Labcorp announces pricing of Fortrea $570 million Notes Offering in connection with anticipated Fortrea spinoff

BURLINGTON, N.C. , June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"), has priced an offering of $570 million of senior secured notes due 2030 (the "Notes"), in

Labcorp announces additional information in connection with its spin-off of Fortrea

BURLINGTON, N.C. , June 12, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, previously announced the following record and distribution dates for its spin-off of Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"): The record date will be 5:00

Labcorp announces information in connection with its spin-off of Fortrea

BURLINGTON, N.C. , June 9, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced the following record and distribution dates for the spin-off of Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"):     The record date will be 5 p.m.

Labcorp announces launch of Fortrea's Notes Offering in connection with anticipated spinoff

BURLINGTON, N.C. , June 8, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a leading global life sciences company, today announced that Fortrea Holdings Inc. , a wholly owned subsidiary of Labcorp ("Fortrea"), has launched an offering of senior secured notes due 2030 (the "Notes"), subject to market